Chassevent A, Allain Y M, Chautard D, Larra F, Lépinard V, Soret J Y
Centre Paul-Papin, Angers, France.
Cancer Radiother. 1998 Apr;2 Suppl 1:12s-15s.
We reassessed the use of DNA flow cytometry in bladder cancers on the basis of our research and already published findings. We discuss technical aspects underlying the validity of the results. Currently, the validity of DNA flow cytometry is established by parametric analysis of the DNA content of tumor cells found in the course of multiple biopsies of the tumor. In addition, we examine the results obtained with bladder washings and, in some cases, the results of biopsies of the bladder mucosa which may appear normal under cystoscopy. The complementarity of these examinations appears to be essential. Our experience confirms the results already published, suggesting that the frequency of DNA aneuploidy increases significantly according to the grade and the tumor stage. However, clinical interpretation of DNA flow cytometry results calls for some caution. There is a general consensus not to use these results in the screening of bladder cancers. However, DNA flow cytometry is particularly useful in the follow-up of carcinoma in situ since DNA aneuploidy is almost always present. DNA flow cytometry is also useful in the stratification of superficial grade 2 tumors. Finally, during the follow-up of invasive tumors, the persistence or appearance of DNA aneuploidy may be attributed to therapeutic resistance.
基于我们的研究及已发表的研究结果，我们重新评估了DNA流式细胞术在膀胱癌中的应用。我们讨论了结果有效性背后的技术层面问题。目前，DNA流式细胞术的有效性是通过对肿瘤多次活检过程中发现的肿瘤细胞的DNA含量进行参数分析来确定的。此外，我们还研究了膀胱冲洗液的检测结果，在某些情况下，还研究了膀胱镜检查下看似正常的膀胱黏膜活检结果。这些检查的互补性似乎至关重要。我们的经验证实了已发表的结果，表明DNA非整倍体的频率根据肿瘤分级和分期显著增加。然而，对DNA流式细胞术结果的临床解读需要谨慎。目前普遍达成共识，不将这些结果用于膀胱癌的筛查。然而，DNA流式细胞术在原位癌的随访中特别有用，因为几乎总是存在DNA非整倍体。DNA流式细胞术在浅表性2级肿瘤的分层中也很有用。最后，在浸润性肿瘤的随访中，DNA非整倍体的持续存在或出现可能归因于治疗耐药性。
